Experts debate benefits and challenges of new ATA guidelines & differentiated thyroid cancer

January 25, 2016

New Rochelle, NY, January 25, 2016--In a stimulating new Roundtable Discussion, a distinguished panel of leading physicians and clinical researchers highlight the key changes, new topics, and areas of ongoing controversy in the "2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer." The Roundtable Discussion ( and the ATA's 2015 Management Guidelines ( are available free to download on the website of Thyroid (, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers ( and the official journal of the ATA.

Led by Moderator Bryan Haugen, MD, University of Colorado School of Medicine, the Roundtable ( features panelists Kenneth Burman, MD, MedStar Washington Hospital Center and Georgetown University, Washington, DC; Ronald Koenig, MD, PhD, University of Michigan Medical Center, Ann Arbor; Susan Mandel, MD, MPH, Perelman School of Medicine, University of Pennsylvania, Philadelphia; Bryan McIver, MD, PhD, Moffitt Cancer Center and Morsani College of Medicine, University of South Florida, Tampa; Steven Sherman, MD, The University of Texas MD Anderson Cancer Center, Houston; Jennifer Sipos, MD, Wexner Medical Center at The Ohio State University College of Medicine, Columbus; and Julie Ann Sosa, MD, MA, Duke Cancer Institute and Duke Clinical Research Institute, Duke University, Durham, NC.

The panelists, some of whom were members of the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer, discussed what they viewed to be the most helpful and the most challenging aspects of the new Management Guidelines, which include eight new questions, 21 new recommendations, and 21 recommendations that were significantly changed from the 2009 Guidelines. The spirited and informative discussion focused on topics such as when to perform total thyroidectomy versus lobectomy, when to use radioiodine therapy, stratifying management based on response to therapy, and how to manage patients when cytologic analysis of a tumor sample yields indeterminate results.

"The guidelines provide a comprehensive framework for the state-of-the-art evaluation, treatment, and surveillance of patients presenting with thyroid nodules and thyroid cancer," says Peter A. Kopp, MD, Editor-in-Chief of Thyroid and Associate Professor of Medicine, Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago. "Compared to the previous version, the updated guidelines integrate an impressive amount of new information and significant advances in the field. While these guidelines form a solid basis for our approach to these common clinical problems, the roundtable discussion and the guidelines also highlight areas that are in need of further investigation and refinements in the future." The Roundtable ( was supported by Rosetta Genomics.

About the Journal

Thyroid (, the official journal of the American Thyroid Association (, is an authoritative peer-reviewed journal published monthly online with open access options and in print. The Journal publishes original articles and timely reviews that reflect the rapidly advancing changes in our understanding of thyroid physiology and pathology, from the molecular biology of the cell to clinical management of thyroid disorders. Complete tables of content and a sample issue may be viewed on the Thyroid website. The complete Thyroid Journal Program includes the highly valued abstract and ( commentary publication Clinical Thyroidology, led by Editor-in-Chief Jerome M. Hershman, MD, and published monthly, and the groundbreaking videojournal companion VideoEndocrinology, led by Editor Gerard Doherty, MD, and published quarterly. Complete tables of content and sample issues may be viewed on the Thyroid ( website.

About the Society

The American Thyroid Association (ATA) ( is the leading worldwide organization dedicated to the advancement, understanding, prevention, diagnosis, and treatment of thyroid disorders and thyroid cancer. ATA is an international membership medical society with over 1,700 members from 43 countries around the world. Celebrating its 92nd anniversary, the ATA delivers its mission -- of being devoted to thyroid biology and to the prevention and treatment of thyroid disease through excellence in research, clinical care, education, and public health -- through several key endeavors: the publication of highly regarded professional journals, Thyroid, Clinical Thyroidology, and VideoEndocrinology; annual scientific meetings; biennial clinical and research symposia; research grant programs for young investigators, support of online professional, public and patient educational programs; and the development of guidelines for clinical management of thyroid disease and thyroid cancer. The ATA promotes thyroid awareness and information through its online Clinical Thyroidology for the Public (distributed free of charge to over 11,000 patients and public subscribers) and extensive, authoritative explanations of thyroid disease and thyroid cancer in both English and Spanish. The ATA website ( serves as the clinical resource for patients and the public who look for reliable information on the Internet.

About the Publisher

Mary Ann Liebert, Inc., publishers ( is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Diabetes Technology & Therapeutics, Journal of Women's Health, and Metabolic Syndrome and Related Disorders. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's more than 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers ( website.

Mary Ann Liebert, Inc./Genetic Engineering News

Related Thyroid Cancer Articles from Brightsurf:

Trends in the global burden of thyroid cancer
This study examined the worldwide trends of thyroid cancer from 1990 to 2017 according to geographic location, sex, age and socioeconomic factors.

Cancer treatment with immune checkpoint inhibitors may lead to thyroid dysfunction
Thyroid dysfunction following cancer treatment with new treatments called immune checkpoint inhibitors is more common than previously thought, according to research that was accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and will be published in a special supplemental section of the Journal of the Endocrine Society.

Thyroid cancer, genetic variations, cell phones linked in YSPH study
Radiation from cell phones is associated with higher rates of thyroid cancer among people with genetic variations in specific genes, a new study led by the Yale School of Public Health finds.

AJR researchers take step toward automating thyroid cancer triage
An article published ahead-of-print in the April issue of the American Journal of Roentgenology (AJR) details how a Stanford University team developed a quantitative framework able to sonographically differentiate between benign and malignant thyroid nodules at a level comparable to that of expert radiologists, which could provide second-opinion malignancy risk estimation to clinicians and ultimately help decrease the number of unnecessary biopsies and surgical procedures.

Thyroid cancer rates in US
An analysis suggests rates of thyroid cancer in the US appear to have plateaued in recent years after decades on the rise.

Using artificial intelligence to predict risk of thyroid cancer on ultrasound
New study uses machine learning on ultrasound images of thyroid nodules to predict risk of malignancy.

For low-risk thyroid cancer patients, less may be more for post-surgery surveillance
Patient self-advocacy is important, and although a maximizing preference may be advantageous in many situations, new research led by the University of Michigan Rogel Cancer Center shows that, in the case of long-term surveillance of treated, low-risk thyroid cancer, health care ''maximizers'' consume more health care resources -- such as doctor visits and diagnostic imaging tests -- which drive up costs without a clear improvement in outcomes.

New test for thyroid cancer could prevent unnecessary surgery
Each year, thanks to inconclusive tests for thyroid cancer, thousands of people undergo unnecessary surgeries to remove part or all of their thyroids.

Raman spectroscopy poised to make thyroid cancer diagnosis less invasive
Researchers have demonstrated that an optical technique known as Raman spectroscopy can be used to differentiate between benign and cancerous thyroid cells.

Are doctors treating more thyroid cancer patients than necessary?
New research may help change treatment practices for patients diagnosed with low risk thyroid cancer.

Read More: Thyroid Cancer News and Thyroid Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to